Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
Revenue of Immuneering Corporation (IMRX)
Revenue in 2023 (TTM): $
According to Immuneering Corporation's latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Immuneering Corporation
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-764,138 | $-58,060,804 | $-53,471,622 | $-53,471,622 |
| 2022 | $316.95 K | $158.83 K | $-51,467,616 | $-50,513,568 | $-49,281,797 |
| 2021 | $2.08 M | $926.89 K | $-33,684,158 | $-33,843,233 | $-33,535,748 |
| 2020 | $2.31 M | $1.03 M | $-17,003,271 | $-17,039,898 | $-17,039,898 |
| 2019 | $1.92 M | $696.74 K | $-7,340,067 | $-7,709,448 | $-8,060,750 |